What 5 Analyst Ratings Have To Say About CARISMA Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, CARISMA Therapeutics (NASDAQ:CARM) received 5 analyst ratings, with 3 being bullish, 2 somewhat bullish, and none being bearish or indifferent. The average price target is $10.8, indicating an upside from the current price of $5.28. This average has increased by 8.0% from the previous average price target of $10.00.
September 06, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CARISMA Therapeutics received positive analyst ratings, indicating potential upside in the short term.
Analyst ratings are a significant factor influencing stock prices. The positive ratings for CARISMA Therapeutics, along with an average price target higher than the current price, suggest potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100